Straumann with clear analyst view, shares tracked against SMI medtech peers

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 10:52.

Straumann Holding AG (CH0012280076) stands in the Swiss medtech spotlight as investors look at analyst views and sector comparisons on the SIX Swiss Exchange. The stock is a key name alongside peers such as Sonova and Sika in the broader SMI and Swiss growth universe.

What analysts are saying today

Consensus data compiled by MarketScreener shows that a clear majority of analysts rate Straumann as Buy or Outperform, while only a minority remain on Hold. Price targets in that sample cluster meaningfully above the current market price, underlining a generally constructive stance. A recent UBS comment on the Swiss medtech space highlights Straumann as a structural growth name next to Sonova, with focus on implant volumes and pricing discipline.

Deutsche Bank and other European brokers have in past months pointed to Straumann’s exposure to premium dental implants and clear aligners as a driver of above-sector growth when patient traffic normalizes further. According to several broker notes aggregated on financial portals, Straumann’s valuation is frequently compared with global peers such as Align Technology and Dentsply Sirona, where investors watch relative earnings momentum and margin resilience closely.

Consensus expectations and earnings focus

Analyst consensus gathered by MarketScreener expects mid-to-high single-digit revenue growth for Straumann in the current year, coupled with a solid EBIT margin in the mid-20s percent range. Bloomberg data indicate that most houses anticipate further incremental margin improvement over the medium term, driven by operating leverage in manufacturing and digital workflows. The next half-year report is generally expected in late summer based on Straumann’s usual reporting cadence, with exact timing guided on the company’s investor relations calendar.

Several broker commentaries emphasize that Straumann’s growth profile depends on procedure volumes in North America, Europe and high-growth markets such as China. In their sector pieces, banks highlight that a recovery in elective dental treatments would support Straumann’s topline, while currency effects and input costs remain important variables for reported margins. For many analysts, Straumann’s balance between premium positioning and emerging-market expansion is a core element of their long-term assumptions.

How Straumann makes its money

Straumann generates most of its revenue with dental implant systems, prosthetic components and related biomaterials for tooth replacement procedures. In recent years, the group has expanded into clear aligner orthodontics under brands such as ClearCorrect, targeting dentists and orthodontists who seek alternatives to established US-based aligner providers. Digital equipment and software for treatment planning and intraoral scanning complement this portfolio and support recurring sales of materials and services.

Where the shares trade today

The Straumann shares (CH0012280076) trade on the SIX Swiss Exchange in Zurich; the latest available indicative price data from exchange feeds and financial portals point to a quotation in Swiss francs with a multi-billion-franc market capitalization for the group as of 2026-06-23, 10:30.

This text is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities.